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ABSTRACT
Objective: To review the use of evidence in the market approval process,
reimbursement, and price control mechanisms for medicines and medical
devices in Thailand, South Korea, and Taiwan.
Methods: Documentary reviews supplemented by interviews with senior
policymakers of relevant public health authorities.
Results: Drug regulatory authorities play a vital role in the market autho-
rization process by considering evidence on safety, efﬁcacy and quality for
new medicines, and bio-equivalence for new generic products of previ-
ously patented medicines. For the formulation of the reimbursement list,
all three cases applied evidence on cost-effectiveness, to various degrees,
with clear institutional structure, capacity, and functions. Only Thailand
has speciﬁed an explicit benchmark on cost-effectiveness for inclusion in
the reimbursement list. For price control, all have established mechanisms
and processes for price negotiation. These mechanisms apply evidence on
cost structure and relative prices in other countries to ensure affordable
prices, especially with the patented drug industry. Thailand’s universal
insurance schemes use a capitation payment model which proves effective
in implicit price control. To increase access to essential medicines that have
patents on and high price, Thailand applied Trade-Related Aspects of
Intellectual Property ﬂexibilities; “government use of patent,” for public
noncommercial purposes to seven essential drugs in 2006 to 2008.
Conclusion: Rapidly increasing health expenditure and universal health
insurance systems have created greater requirement for proof of “value for
money” in the approval and funding of new medical technologies. All
settings have established clear mechanisms to apply appropriate evidence
in the processes of market approval, reimbursement, and pricing control.
Keywords: economic analysis, economic evaluation, economic outcome,
health-care decision makers, health economics.
Introduction
One of the main targets of health policy formulation is to ensure
the efﬁcient use of limited resources, requiring efﬁcient and trans-
parent use of evidence to inform sound decision-making. This is
particularly relevant to decisions relating to the approval and
reimbursement of health technologies such as drugs, diagnostics,
treatment procedures, and medical devices. In countries with
large health insurance schemes, especially publicly funded uni-
versal ones, there is usually very strong demand to achieve
maximum “value for money.” In Asia-Paciﬁc, Thailand, South
Korea, and Taiwan have health systems developed particularly
rapidly to achieve universal health insurance, based on public
policies and legislation. All are further characterized by the
increasing reliance on scientiﬁc and economic evidence to inform
decision-making within their health systems. Medical technolo-
gies, including medicines, medical devices, and diagnostics are
subject to intensive formal review and assessment of their “value
for money” before allowing their market approval and their
reimbursement within the universal health insurance schemes.
In the 3rd Asia-Paciﬁc Conference of the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR), rep-
resentatives of the three cases reviewed the mechanisms and the
processes used to assess new health technologies. Many similari-
ties as well as differences were evident. This article aims to
compare and critically assess the national mechanisms and pro-
cesses in generating and applying evidence to inform policy deci-
sions on health technologies relating to: 1) market authorization;
2) price control; and 3) reimbursement and ﬁnancial control
policies of health technologies in three settings. It is expected that
results from this study will be useful for international compari-
son and providing input for decision-makers who seek to reform
or strengthen the use of evidence in decision-making.
Methods
This article was synthesized from three articles presented at the
3rd ISPOR conference in Seoul on September 6, 2008. Each
article was developed based on extensive documentary reviews
supplemented by interviews with senior administrators of rele-
vant public health authorities.
In Thailand, information was collected from the Drug
Control Division, Medical Device Control Division, Medium
Price Setting Committee, and the Subcommittee for Development
of the National List of Essential Drugs (NLED) which is under
the Thai Food and Drug Administration (FDA), and from the
Beneﬁt Package Subcommittee of the National Health Security
Board.
In South Korea, information was collected from the Korean
Food and Drug Administration, the Health Insurance Review
and Assessment Service (HIRA), and the National Health Insur-
ance Corporation (NHIC).
In Taiwan, information was collected from the Bureau of
Food and Drugs Analysis and the Center for Drug Evaluation
(CDE), the Drug Beneﬁt Committee and the Devices Beneﬁt
Committee under the Bureau of National Health Insurance
(NHI).
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Results
The National Health Insurance Systems
All settings have well-established National Universal Health
Insurance systems. The beneﬁt packages are extensive and include
all high cost health care and drugs. The differences liemainly in the
source of funding and in the provider payment mechanisms.
In Thailand, there are three public health insurance schemes
cover the entire population. The Civil Servant Medical Beneﬁt
Scheme (CSMBS) covers 8% of the population, funded totally
from tax revenue and pays providers based on a retrospective fee
for service reimbursement system. The Social Security Insurance
Scheme (SSS) covers private employees, 15% of the population,
funded equally from the tax revenue, the employers and the
employees. The Universal Health Insurance (UC) or the “gold
card” scheme covers the rest of the population and is funded
entirely by tax revenue. There is essentially no, or very little,
co-payment in any of the three schemes. The SSS and the UC
schemes pay providers based on a close ended prepaid-capitation
budgetary system. This payment system puts the ﬁnancial risk on
the providers, so drugs and medical devices are prescribed more
cautiously. Nevertheless, it may result in underprescription and
insufﬁcient use of essential drugs and medical devices. Table 1
compares the key characteristics of each scheme.
South Korea and Taiwan are managed by a single National
Health Insurance mechanism, funded either by premium contri-
butions or tax revenue together with employment-based funding
and co-payments by the patients. Providers are paid by a fee for
services retrospective reimbursement system. There is a list of
treatments that speciﬁes those that are entitled to reimbursement,
supplemented by substantial copayments by patients. Such fee-
for-service systems tend to support extensive or over use of drugs
and technologies, as the providers are not responsible for the
cost, or may even further proﬁt from its inﬂation.
Health expenditure in each case is increasing at a rate higher
than economic growth. The universal health insurance systems
are pushed to be more stringent in assessing the “value for
money” of all medical technologies that are included in the
beneﬁt package of each scheme.
Mechanisms and Evidence Used in
Market Authorization
All settings have well-established drug and medical device regu-
latory authorities that require evidence on quality, safety, and
efﬁcacy for market authorization, with few differences among
them, the details of which are shown in Table 2. It is noteworthy
that Thailand has a 2-year temporary market authorization of
new drugs, pending the result of a Safety Monitoring Program
[1–6]. In South Korea, there is no need for people involved in the
process to declare their Conﬂict of Interest (COI). None currently
require cost-effectiveness information for market authorization;
however, in the Thai revised drug bill, there is an article that
requires cost-effectiveness information for market authorization,
for which approval is pending.
Mechanisms, Processes, and Evidences Used in
Decisions for Reimbursement
All three cases have established institutions to generate and apply
evidence on cost-effectiveness in their decisions to include new
technologies in the insurance schemes’ reimbursement list
referred to as the “reimbursable list” in South Korea and Taiwan,
and as the “beneﬁt package” in Thailand [7]. This is because the
health insurance systems in South Korea and Taiwan pay pro-
viders based on a fee schedule for services, while Thailand pays
providers based on a prospective capitation system.
South Korea has the most advanced capacity in generating
and use of evidence on cost-effectiveness, while Taiwan and
Thailand have been established in the last 2 years. There is no
speciﬁc timeline to have advance pharmacoeconomic (PE) system
of review; however, both cases have been generating PE activities;
publishing PE guideline or submission guideline [8,9] and train-
ing for pharmacoeconomists.
Table 1 Characteristics of the three public health insurance schemes in Thailand
Characteristics
Public health insurance schemes
UC SSS CSMBS
Feature State welfare Social insurance Fringe beneﬁt
Legal framework National Health Security Act B.E.2545
(2002)
Social Security Act B.E.2533 (1990) Medical Beneﬁts for Civil Servants and
Public Employees Act B.E.2521 (1978)
Eligible population coverage Anyone who is not covered by the SSS
and CSMBS
All private employees and temporary
public employees
All civil servants and permanent public
employees, retirees, and their
dependents
Population coverage in 2007 46,512,000 7,732,000 4,956,000
Source of ﬁnances General tax revenue Equal contribution from employers,
employees, and the Government
General tax revenue
Payment mechanism for
health services
Capitation based on hospital expenditure
(Capitation contract model)
Capitation based on hospital expenditure
(Capitation contract model)
Fee-for-service retrospective
reimbursement model
Expenditure per capita
(2007 Thai Baht)
2,089 2,200 8,462
Note: Approximately 2% of the population is covered by voluntary private health insurance systems and around 3% are not covered by any health insurance scheme.
Source: Adapted from Thailand Health Proﬁle 2005 to 2007 [19,20].
UC, Universal Health Insurance; SSS, Social Security Scheme; CSMBS, Civil Servant Medical Beneﬁt Scheme.
Table 2 The market authorization process inThailand, South Korea, and
Taiwan
Regulatory authorities that play
a vital role in market
authorization
Thai FDA, Korean FDA,Taiwan DOH,
Bureau of Food and Drug Analysis and
the Center for Drug Evaluation
Mandatory evidence required • Safety, efﬁcacy, quality for new
medicines
• Bio-equivalence for generic products of
new medicines
Noteworthy issues in the
process
• Thailand: 2-year temporary license and
SMP granted for all new drugs which
provide market exclusivity, before
granting a permanent license
• South Korea: 2 steps licensing for
medical devices: article review and
market approval by GMP accreditation
Thai FDA, Thai Food and Drug Administration; Korean FDA, Korean Food and Drug
Administration; DOH, Department of Health; SMP, Safety Monitoring Program; GMP, good
manufacturing practice.
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Table 3 summarizes the key features of the reimbursement
systems in the three settings.
Thailand. Under the regulation of Prime Minister Ofﬁce
B.E.2535 (1992) on public procurement, the NLED is a list of
drugs, vaccines, radioactive substances, and disinfection agents
that are necessary for prevention and control of all major health
problems. The regulation mandates the Ministry of Public Health
(MOPH) to develop the NLED and a “medium price” or “ref-
erence price” list of each drug in the NLED [10,11]. The NLED
is about 50% bigger than the World Health Organization’s
model list of essential medicine [12]. They tend to be the
optimum list of medicines for basic health-care system including
673 items of active ingredients or 892 dosage forms followed 17
categories of British National Formulary [11]. All public health-
care facilities are required to procure the drugs using government
budget based on the NLED and within the medium price. The
NLED constitutes the list of drugs that are reimbursable in the
three public health insurance systems (Table 1). It also aims to be
used as a tool to encourage the rational use of medicines [11].
The cost of prescribed drugs outside the NLED is born by indi-
viduals under the SSS and UC systems; under the CSMBS system,
three attending physicians can approve the use of drugs outside
of the NLED.
Figure 1 illustrates the development of the NLED. The
National Drugs System Development Committee appoints senior
decision-makers, health professionals, academics, and representa-
tives of the public health insurances schemes as members of the
NLED Subcommittee, and authorizes them to develop the NLED.
The development also requires a number of outstanding medical
specialists throughout the country to work for 16 Speciﬁc
Working Groups as well as health economists to work for the
Health Economic Working Group. All parties involved require a
declaration of COI during the development of the NLED.
The evidence used includes safety, efﬁcacy, and efﬁciency
where the latter was added in the revision of the NLED 2004 and
2008. Evidences on drug safety and efﬁcacy are synthesized and
considered by the Working Groups. The Health Economic
Working Group commissioned Health Intervention Technology
Assessment Program (HITAP), an independent research institute
under the MOPH, to conduct PE assessments. Results of these
studies are subsequently considered by the Subcommittee for
inclusion/exclusion of these drugs from the NLED. HITAP has
also developed guidelines on PE studies which have been
approved by the Subcommittee on the NLED of the Thai FDA,
and the Beneﬁt Package Subcommittee of the National Health
Security Board [9]. These guidelines are therefore accepted as the
Thai National Guidelines. The two subcommittees also agreed
on a “benchmark” of cost-effectiveness to include new technolo-
gies in the beneﬁt package. Any technology with a cost per
quality-adjusted life-year gained below the average gross domes-
tic product (GDP) per capita is considered acceptable for inclu-
sion on the NLED.
There was no reimbursement list for medical devices in
Thailand. The coverage of medical devices varies largely among
the three public schemes. CSMBS post-paid almost all medical
devices though a ﬁxed rate fee-for-service payment while UC
and SSS include the use of medical devices as part of their basic
health packages and paid for based on prepaid capitation
(Table 1).
South Korea. Since 2007, it has been mandatory to submit PE
evidence on new medicines for the purpose of reimbursement.
Depending on the extent of improved effectiveness of new medi-
cines compared with that of their main comparator, different PE
frameworks apply. If it is claimed that a new medicine shows
improved effectiveness, cost-effectiveness or cost-utility analysis
is required. In this case, the incremental cost-effectiveness ratio is
a central criterion for the reimbursement decision. If the effec-
tiveness of new medicine is similar or noninferior to that of the
main comparator, then cost-minimization analysis sufﬁces for the
reimbursement decision.
Decisions on reimbursement of new medicines are made by
the Pharmaceutical Beneﬁt Assessment Committee (PBAC) of
HIRA. A subcommittee can be commissioned to review effective-
ness and cost-effectiveness on a scientiﬁc basis before PBAC’s
decision. Decisions made by PBAC are based on a majority vote.
Where this process fails to attain a clear decision, the Ministry of
Health, Welfare and Family Affairs has the ﬁnal say on the
reimbursement of the medicine of interest.
Figure 2 shows the reasons for deciding not to reimburse new
medicines between 2005 and 2007. Compared with year 2005,
the percentage of medicines that were not reimbursed for lack of
evidence on clinical effectiveness reduced signiﬁcantly in 2007,
while the share of medicines not reimbursed for lack of evidence
on cost-effectiveness increased by 22 percentage points (to see
these reasons).
Since the introduction of mandatory submission of PE evi-
dence, academic societies concerned have been providing educa-
tion programs for training pharmacoeconomists in both public
and private sectors in line with the government’s policy. Thus, in
spite of the current lack of experts in PE arena, the policy that
requires PE evidence in the decision-making for reimbursement
of new medicines is expected to keep its way.
Taiwan. When submitting the application to the Drug Beneﬁt
Committee of Bureau of National Health Insurance (BNHI),
pharmaceutical companies have to provide evidence of effective-
ness. Usually, this will include published articles on clinical trial
results and technical reports. Occasionally, a pharmaceutical
company will also provide results of local trials.
Currently, the BNHI does not require systematic reviews of
effectiveness or PE information, or to conduct such local studies.
Table 3 Reimbursement systems in Thailand, South Korea, and Taiwan
Cases Key features of the reimbursement systems
Thailand • Medicines previously selected in the NLED are
included in the beneﬁt packages of all three
national health insurance schemes
• The 2007 revision of NLED required cost-
effectiveness evidence produced by the newly
founded Health Intervention and Technology
Assessment Program
South Korea • Medicines are assessed by HIRA for reimbursement
list based on clinical beneﬁts, cost-effectiveness,
budget impact, and price of similar medicines in
other countries.
• PE evidence for new medicines is mandatory for
reimbursement
Taiwan • Listing in the National Health Insurance formulary
requires evidence on effectiveness; cost-
effectiveness is not mandatory
• In 2007, the HTA Division was established under
the Centre for Drug Evaluation to provide
supporting information on cost-effectiveness to the
Bureau of NHI
Concluding remarks All applied evidences on cost-effectiveness in the
decision on reimbursement of medicines with clear
institutional structure, capacity, and functions
NLED, National List of Essential Drugs; HIRA, Health Insurance Review and Assessment
Service; PE, pharmacoeconomic; HTA, health technology assessment; NHI, National Health
Insurance.
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The only mechanism to control the expenditures of a new drug is
the 3-year agreement policy applied to those drugs whose esti-
mated budget impact is greater than 100 million NTD per year
(about US$3.1 million). The review system for health technology
under the NHI in Taiwan slightly differs for new drugs and for
new devices/materials. The Drug Beneﬁt Committee is in charge
drug listing, pricing, and prescribing guidelines. The Device
Beneﬁt Committee, on the other hand, is in charge of the listing,
pricing, and usage guidelines for new devices.
Responding to the lack of PE data in the review process, the
CDE added the health technology assessment (HTA) division to
its services in October 2007 [13,14]. The CDE is a nonproﬁt
organization established by the Department of Health (DOH).
The HTA division will provide evidence to the Drug Beneﬁt
Committee/BNHI on comparative effectiveness and cost-
effectiveness. It primarily uses secondary data and published
literature to generate the relevant evidence.
The guiding principle for listing is the demonstrated effective-
ness as shown in the literature. There are, however, a few con-
ditions that may prohibit the intervention from being listed, such
as when the budget impact is expected to be huge, where there
are similar products on the list, or the existence of severe adverse
effects.
Mechanisms, Processes, and Evidence Used in Decisions
on Pricing
In each country, there are clear mechanisms to regulate prices of
medicines listed on the “reimbursable list” or the “beneﬁt
package.” Evidence on cost structure, relative prices in other
countries, and negotiations between health insurance funds are
common mechanisms to ensure reasonable prices. Thailand also
effectively introduced compulsory licenses, which is a ﬂexibility
measure allowed by the Agreement on Trade-Related Aspects of
Intellectual Property (TRIPS). This aimed to pursue generic com-
petitions and price reductions of patented products.
Thailand. Several mechanisms have been used for price control
of drugs and medical devices. Most goods available in the market
are determined generally by market mechanisms driven by supply
The National Drugs System 
Development Committee 
Endorsement of NLED 
Setting concept, philosophy 
and criteria for drug selection 
Making final decision from the 
proposal of all the Working 
groups. 
The Working group for 
coordination & consolidation of 
NLED 
16 Specific Working Groups for 
NLED selection 
NLED secretariats 
Gathering information and 
making recommendations to the 
Subcommittee 
Reviewing evidences, 
requesting more information 
and making recommendations 
to the Working group for 
coordination & consolidation of 
NLED 
Screening drug applications 
submitted by pharmaceutical 
companies 
Gathering and generating 
evidence in terms of ISafE and 
EMCI, if applicable 
The Health 
Economic Working 
Group
Reviewing and generating 
pharmacoeconomic evidence 
for selected medicines 
The Subcommittee for 
Development of the NLED 
NLED publication 
Figure 1 The process of theThai National List of
Essential Drugs (NLED) development (Adapted
from Chongtrakul P, Sumpradit N andYoongthong
W [18]).
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and demand; however, different mechanisms have been applied
for medicines. For the price labeling of over-the-counter (OTC)
drugs, the control of the Ministry of Commerce over drug prices
are mandatory under the Prices of Goods and Services Act
B.E.2542 (1999). The evidence used for price setting of OTC
drugs includes information on cost structures and international
prices submitted by pharmaceutical companies.
On the other hand, prices of non-OTC drugs include in the
NLED procured by public hospitals, controlled by the “Medicine
Price Ceiling,” which is a list of maximum prices for each drug
that sellers are allowed to charge from public hospitals [10]. The
ceiling price is set by the Committee for Development of the
Medicine Price List based on collective information on purchas-
ing prices of similar drugs from all public hospitals [10]. The
information collected by the committee is also used in the “Ref-
erence Prices of Medicines” database and is publicly available
through the website of the Drugs and Medical Supplies Informa-
tion Center (http://dmsic.moph.go.th/index.php) [10]. Public
hospitals can use this information for negotiating with pharma-
ceutical companies before subsequent purchases. There was no
price ceiling and reference set for medical devices, and prices are
based entirely on market supply and demand.
In the case of bulk purchasing at the national and provincial
levels, prices of drugs and medical devices are also controlled by
other effective mechanism [15]. This is particularly with drugs
and medical devices which are widely used in very high quantities
and include antibiotics, diabetes, antihypertensive, condoms, and
others.
Recently, the Thai MOPH endorsed the use of generic forms
of seven patented drugs for public noncommercial purposes
under article 51 of the Thai Patent Act B.E.2535 (1992), which
complies with article 31(b) of the World Trade Organization
Agreement on TRIPS and the Doha Declaration on Intellectual
Properties and Public Health. These consisted of efavirenz,
lopinavir/ritonavir, clopidogrel, imatinib, docetaxel, erlotinib,
and letrozole. The policy allowed the Government Pharmaceuti-
cal Organization (GPO) to import generic products of the issued
drugs from Indian pharmaceutical companies as well as produc-
ing them locally by the GPO resulting in a signiﬁcant reduction in
price of these particular drugs.
South Korea. In the case of medicines, a price-volume arrange-
ment was introduced to control expenditures. Manufacturers or
importers are required to submit the expected sales for their
products when they apply for reimbursement in the NHI. Con-
sidering budget impact, NHIC negotiates a price for the medicine
based on the expected sales amount. If actual sales exceed
expected ones for a speciﬁed period after approval for reimburse-
ment in the NHI, the price of the medicine of interest is reduced
accordingly. For example, if actual sales exceed expected ones by
more than 30% for 1 year after reimbursement, the price of the
medicine is expected to be lowered by approximately 10%.
In 2007, as an additional containment measure for reim-
bursement by the NHI, a positive list system was instated to
replace the negative one; all drugs that were previously eligible
for reimbursement were initially placed on the positive list, with
a 5-year timeframe for their reevaluation.
The main criterion for keeping drugs on the list is cost-
effectiveness. If a drug proves not cost-effective, in principle, it
should be excluded from the list. Nevertheless, if its manufac-
turer wants to lower its price to the extent to which it becomes
cost-effective, then the drug can remain on the list. In the case of
migraines, for example, 3 out of 11 chemicals were found to be
not cost-effective. As a result, one chemical was excluded from
Figure 2 Reasons for decision not to reimburse
new medicines in South Korea. Source: Health
Insurance Review and Assessment Service.
Table 4 Annual drug costs and growth rates of the National Health
Insurance (NHI) in Taiwan, 1998–2007
Year
NHI Exp. (Annual
growth rates, %)
Drug costs (Annual
growth rates, %)
Drug costs as
% NHI exp.
1998 290.9 (11.4) 72.3 (12.9) 24.8
1999 316.6 (8.8) 80.4 (11.13) 25.4
2000 326.0 (2.9) 82.9 (3.1) 25.4
2001 341.7 (4.8) 84.7 (2.2) 24.8
2002 370.9 (8.5) 90.5 (6.9) 24.4
2003 383.9 (3.3) 94.5 (4.3) 24.6
2004 438.8 (14.1) 109.4 (15.7) 24.9
2005 452.4 (3.1) 112.1 (2.4) 24.8
2006 456.4 (0.9) 114.1 (1.8) 25.0
2007 473.8 (3.8) 117.0 (2.5) 24.7
Source: [16,17] (USD 1 = 32 NTD in 2005).
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the list while the other two were kept on it by lowering their
prices.
Taiwan. The BNHI has introduced many strategies to control
health expenditure. These strategies include price adjustment
based on the prices of international products; existing products
(inter-brands comparison) or market price and volume survey;
delegation of ﬁnancial responsibility to regional bureaus;
co-payment for outpatient drugs; generic grouping (a reference
pricing scheme based on chemical equivalence); a global budget
payment system for clinics and hospitals; and reduction of ﬂat
daily payment rate of drugs for clinics.
After an increase in overall drug costs in the NHI from 62.2
billion NTD (about 1.9 billion USD) in 1996 to 94.5 billion NTD
in 2003, Lee et al. [16] carried out a time-series analysis of the
impact of the various price control strategies on the growth rate
of drug costs. Recent information from BNHI as of May 2008
shows that drug costs reached 117 billion NTD in 2007 [16].
Three strategies, consisting of generic grouping, delegation of
ﬁnancial responsibility, and reduction on ﬂat payment rate of
clinics, were signiﬁcantly associated with the reduction of drug
costs. Hospital global budgets, however, offset partial savings
from the above-mentioned three strategies.
Cumulative savings during the study period were estimated to
be 25.4 billion NTD (about 0.80 billion USD) [16]. Of all the
strategies, generic grouping had the most signiﬁcant effects on all
models except for outpatient clinics. Reduction of ﬂat payments
and delegation of ﬁnancial responsibility were signiﬁcantly asso-
ciated with drug cost reductions in clinic and inpatient sectors,
respectively. Nevertheless, neither drug co-payment nor price
adjustment based on international or interbrand price compari-
son had signiﬁcant impact on drug costs (Table 4) [16,17].
Discussion and Conclusion
The establishment of universal health insurance systems with
rapidly increasing health expenditure poses considerable chal-
lenges to policymakers having to decide which interventions are
to be authorized and funded in the formal health sector. This
study reveals actors and processes involved in generating, using
and applying evidence to inform policy decisions on the
approval, price control, and reimbursement of health technolo-
gies in three Asia-Paciﬁc countries. These cases have achieved
universal coverage for their populations amidst rapid develop-
ment within and beyond the health-care system.
All three settings applied evidence for market authorization
relating to efﬁcacy and safety, but not to cost-effectiveness; Thai-
land, however, is considering applying PE evidence in the market
authorization process, as detailed in the forthcoming drug bill.
The existence of UC schemes proves to be an enabling envi-
ronment for price control through the application of reimburs-
able medicine lists (or the “beneﬁt package” in the case of
Thailand), where cost-effectiveness plays a vital role as a criterion
for inclusion on the list. Use of economic evaluation data is
mandatory in the Korean setting to get approval in the reimburs-
able list. In Thailand and Taiwan, on the other hand, it is con-
sidered as supplementary data.
Ideally, it would be government-appointed bodies that would
produce the evidence to inform decision-making on the approval
and reimbursement of new health technologies; however, limited
human resources restricts the ability to do so. Such limitations in
capacity need to be considered before applying cost-effectiveness
analyses as a key criterion for the inclusion of new technologies
in the reimbursable list or beneﬁt package. South Korea has tried
to resolve this challenge by allowing the industry to produce the
necessary evidence, with guidelines set by the government to
ensure the quality of research. In Thailand, where HITAP is
currently responsible for the gathering of PE data, the newly
developed guidelines suggest a shift toward the Korean and Tai-
wanese systems where pharmaceutical industry or importers can
submit economic evaluation data.
It is noteworthy that although evidence-based decision-
making has been applied in all processes within the three settings
with respect to drugs, this has not been the case with medical
devices in the Thai setting.
The enhancement of evidence-based decision-making is found
throughout the health-care systems of Thailand, South Korea,
and Taiwan. Table 5 summarizes the key areas where evidence-
based decision-making has been established in the three coun-
tries. With the increasing use of evidence to inform their decision-
making, the 3rd Asia-Paciﬁc Conference of the ISPOR has
recognized these three cases as having rapidly changing systems
compared with other members of the Asia-Paciﬁc region. The
lessons learnt from this article might be useful for other nations
that seek to enhance the use of the scientiﬁc-based data in general
and economic evaluation data in particular in developing their
health policy.
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